Lonafarnib is a sensitive CYP3A4 substrate. Haloperidol will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increases lomitapide levels several folds. Haloperidol increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval. Lefamulin will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Haloperidol and indapamide both increase QTc interval. Haloperidol and ibutilide both increase QTc interval. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Haloperidol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors. Haloperidol increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.Ĭomment: Increases risk of neuroleptic malignant syndrome.ĭisopyramide and haloperidol both increase QTc interval. Monitor ECG and QT interval (QT prolongation may occur with cumulative doses ≥35 mg torsades de pointes reported with single doses ≥20 mg)Ġ.5-2 mg PO q8-12hr initially if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined)ġ2 years: Moderate disease, 0.5-2 mg PO q8-12hr initially severe disease, 3-5 mg PO q8-12hr not to exceed 30 mg/day Tourette Disorderġ2 years: 0.5-2 mg PO q8-12hr initially if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined) Behavioral Disordersġ2 years: 0.5-3 mg PO, repeated in 1 hour PRN alternatively, 2-5 mg IM, repeated in 1 hr PRNĮither increases toxicity of the other by Other (see comment).2-10 mg initially, depending on degree of agitation if response inadequate, may repeat bolus q15-30min, sequentially doubling initial bolus dose when calm achieved, administer 25% of last bolus dose q6hr taper dose after patient is controlled.May be needed for ICU delirium use only haloperidol lactate for IV administration do not use haloperidol decanoate.Maintenance: Monthly dose 10-15 times daily PO dose.Initial: IM dose 10-20 times daily PO dose administered monthly not to exceed 100 mg if conversion requires initial dose >100 mg, administer in 2 injections (eg, 100 mg initially, then remainder in 3-7 days).2-5 mg q4-8hr PRN may require q1hr in acute agitation not to exceed 20 mg/day.Severe disease, 3-5 mg q8-12hr initially not to exceed 30 mg/day.Moderate disease, 0.5-2 mg q8-12hr initially.
0 Comments
Leave a Reply. |